Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
23 September 2016Website:
http://www.acimmune.comNext earnings report:
06 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 14 Nov 2024 22:47:03 GMTDividend
Analysts recommendations
Institutional Ownership
ACIU Latest News
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032.
AC Immune S.A. saw its shares surge by over 50% in premarket trading on Monday following the announcement of a licensing agreement with Takeda Pharmaceutical Co. for an experimental Alzheimer's disease vaccine.
AC Immune stock is rising on Monday following the release of its first quarter 2024 earnings report, which includes details of a new collaboration with Takeda Pharmaceutical.
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market action during the post-pandemic period.
Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
What type of business is AC Immune SA?
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
What sector is AC Immune SA in?
AC Immune SA is in the Healthcare sector
What industry is AC Immune SA in?
AC Immune SA is in the Biotechnology industry
What country is AC Immune SA from?
AC Immune SA is headquartered in Switzerland
When did AC Immune SA go public?
AC Immune SA initial public offering (IPO) was on 23 September 2016
What is AC Immune SA website?
https://www.acimmune.com
Is AC Immune SA in the S&P 500?
No, AC Immune SA is not included in the S&P 500 index
Is AC Immune SA in the NASDAQ 100?
No, AC Immune SA is not included in the NASDAQ 100 index
Is AC Immune SA in the Dow Jones?
No, AC Immune SA is not included in the Dow Jones index
When was AC Immune SA the previous earnings report?
No data
When does AC Immune SA earnings report?
The next expected earnings date for AC Immune SA is 06 February 2025